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ABSTRACT 43 
 44 
Aims: Cerebrovascular disease is one of more typical reasons for hospitalisation and re-45 
hospitalisation in people with type 2 diabetes. We aimed to derive and externally validate two risk 46 
prediction algorithms for cerebrovascular hospitalisation and re-hospitalisation. 47 
Methods: Two independent cohorts were used to derive and externally validate the two risk 48 
scores. The development cohort comprises 4,704 patients with type 2 diabetes registered in 18 49 
general practices across Cambridgeshire. The validation cohort includes 1,121 type 2 patients from 50 
a post-trial cohort data.  Outcomes were cerebrovascular hospitalisation within two years and 51 
cerebrovascular re-hospitalisation within ninety days of the previous cerebrovascular 52 
hospitalisation. Logistic regression was applied to derive the two risk scores for cerebrovascular 53 
hospitalisation and re-hospitalisation from development cohort, which were externally validated 54 
in the validation cohort.  55 
Results: The incidence of cerebrovascular hospitalisation and re-hospitalisation was 3.76% and 56 
1.46% in the development cohort, and 4.99% and 1.87% in the external validation cohort. Age, 57 
gender, body mass index, blood pressures, and lipid profiles were included in the final model. 58 
Model discrimination was similar in both cohorts, with all C-statistics > 0.70, and very good 59 
calibration of observed and predicted individual risks.  60 
Conclusion: Two new risk scores that quantify individual risks of cerebrovascular hospitalisation 61 
and re-hospitalisation have been well derived and externally validated. Both scores are on the 62 
basis of a few of clinical measurements that are commonly available for patients with type 2 63 
diabetes in primary care settings and could work as tools to identify individuals at high risk of 64 
cerebrovascular hospitalisation and re-hospitalisation. 65 
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 70 
INTRODUCTION 71 
Type 2 Diabetes as a risk factor for cerebrovascular diseases has been found to be markedly 72 
associated with increased risk of cerebrovascular mortality. One meta-analysis revealed that in 73 
comparison with people without diabetes, people with diabetes had a 2.27-fold of increased risk 74 
of cerebrovascular disease [1]. As cerebrovascular disease is one of the major causes of death and 75 
disability in people with type 2 diabetes [2], risk algorithms to predict cerebrovascular disease 76 
have been increasingly developed to facilitate the effective management of high risk individuals 77 
[3].  78 
 79 
It is common for people with diabetes to be admitted to hospital, with one in five inpatients 80 
having diabetes in some age groups in England [4]. Cerebrovascular diseases is one of the more 81 
common causes for hospitalisation in patients with type 2 diabetes [5]. And it is also common for 82 
patients with type 2 diabetes to be re-hospitalised for cardiovascular or cerebrovascular disease 83 
[6]. The associated increased inpatient costs are marked factors to the health burden borne by 84 
heath care system as a result of diabetes and often reflects manageable morbidities suffered by 85 
patients with diabetes. A prediction tool to identify individuals at particularly high risk of 86 
cerebrovascular hospitalisation and re-hospitalisation would facilitate subsequent more intensive 87 
interventions.  88 
 89 
A systematic review identified 12 risk scores to predict coronary heart or cerebrovascular disease 90 
conducted in patients with type 2 diabetes [7]. However among the 12 risk scores only two were 91 
developed for stroke and neither had external validation [7]. So far, there have been no 92 
prediction models developed for cerebrovascular disease in people with type 2 diabetes. 93 
Furthermore there have been no models derived and validated to predict cerebrovascular 94 
hospitalisation and re-hospitalisation in type 2 diabetes patients.  95 
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 96 
The objective of this study was to derive and externally validate new risk prediction algorithms 97 
based on reliable ordinary clinical measurements recorded in primary care settings for 98 
cerebrovascular hospitalisation within the following two years and cerebrovascular re-99 
hospitalisation within 90 days of a prior cerebrovascular hospitalisation. 100 
 101 
MATERIAL AND METHODS 102 
Data setting and study population 103 
Two prospective cohorts derived from Cambridgeshire, the United Kingdom were utilised in this 104 
study. The derivation cohort included primary care electronic health record data and was used to 105 
derive risk algorithms to predict cerebrovascular hospitalisation and re-hospitalisation. The 106 
external validation cohort included post-trial data and was utilised to externally validate the two 107 
risk algorithms.   108 
Derivation cohort 109 
The derivation cohort included type 2 diabetes patients registered in 18 general practices across 110 
Cambridgeshire, England, in 2008/2009 with linkage to inpatient hospitalisation (Secondary Uses 111 
Service (SUS)) data as part of a review of diabetes care across Cambridgeshire by the local health 112 
board, National Health Service (NHS) Cambridgeshire. Egton Medical Information Systems (EMIS) 113 
general practitioner (GP) software system was used in the cohort practices, from which a 114 
predefined dataset could be extracted. No systematic selection process for these surgeries was 115 
applied, and data extracted were for the whole diabetes population. The follow-up 116 
hospitalisation data to 2010–2011 was available to all patients in the derivation cohort. Inpatient 117 
hospitalisation to private and NHS hospitals within or outside Cambridgeshire were followed up. 118 
Personal identifiers were not released to researchers, and only anonymized datasets were used 119 
to conduct all subsequent analyses.  120 
Validation cohort 121 
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The validation cohort is a post-trial cohort derived from the RAndomized controlled trial of Peer 122 
Support in type 2 Diabetes (RAPSID) [8]. The design and research methods of the RAPSID have 123 
been previously published [8].  In brief, RAPSID was designed as a 2x2 factorial cluster 124 
randomized controlled trial comparing 4 arms: 1:1 peer support, group peer support, combined 125 
support (1:1 plus group peer support) and control in patients with type 2 diabetes. All eligible 126 
patients had their type 2 diabetes diagnosed for at least twelve months and those having 127 
psychotic illness or dementia were ruled out. Patients were recruited from local communities 128 
cross Cambridgeshire and its neighbouring areas of Hertfordshire and Essex.  Post-trial follow-up 129 
data were only available for patients residence in Cambridgeshire and its neighbouring areas of 130 
Hertfordshire that are served by the Cambridgeshire and Peterborough Clinical Commissioning 131 
Group (CCG).  The intervention was implemented following a pilot in a framework defined by 132 
Peers for Progress [9].  The intervention duration was 8-12 months and was concluded between 2 133 
June 2011 to 12 April 2012 [10, 11].  134 
 135 
Demographic data, HbA1c, lipid profiles and blood pressure data were collected at baseline. Every 136 
eligible patient was followed up till 30 June 2015 (0.91-4.07 years of follow-up from 137 
beginning/entry date).  Inpatient hospitalisation (NHS & private hospitals), Accident & Emergency 138 
(A&E) and outpatient episodes within or outside Cambridgeshire and the included areas of 139 
Hertfordshire were collected through Cambridgeshire and Peterborough Clinical CCG [12, 13] and 140 
stored as the International Classification of Diseases (ICD-10) codes [14].  141 
 142 
Definition of cerebrovascular hospitalisation and re-hospitalisation 143 
The main outcomes in our study are cerebrovascular hospitalisation and rehospitalisation. The 144 
cerebrovascular hospitalisation was defined as having ≥1 hospitalisation with cerebrovascular 145 
disease (CeVD) as the primary diagnosis (ICD-10: I60–I69 in the first ICD field) over the two-year 146 
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follow-up and cerebrovascular re-hospitalisation was defined as having ≥1 CeVD re-hospitalisation 147 
within ninety days of prior CeVD hospitalisation.  148 
Potential predictors, missing data, and power estimation 149 
Objective clinical measurements including systolic and diastolic blood pressure, body mass index, 150 
glycated haemoglobin (HbA1c) and serum lipid profiles were used as predictors in the models to 151 
facilitate the external application of the scores. Demographic characters, (sex and age) and 152 
whether the patient was prescribed lipid-lowering medicine were also incorporated in our 153 
models. In the UK primary care settings, diabetes patients were informed to have their blood 154 
pressure and metabolic measurements examined at least once a year since the date of diabetes 155 
diagnosis and the most recent measurement was recorded before 1 April 2009 (giving a minimum 156 
of fifty days before the first inpatient hospitalisation). The length of diabetes was not commonly 157 
recorded, and therefore was not usefully accessible for the model derivation. The specific 158 
treatment for diabetes and anti-hypertensive therapy were not accessible in this study. Lipid-159 
lowering prescription was recorded. 160 
 161 
Missing information in the derivation cohort included body mass index (3.17%), systolic blood 162 
pressure (9.95%), diastolic blood pressure (9.95%), total cholesterol (12.35%), high-density 163 
lipoprotein cholesterol (14.56%), and low-density lipoprotein cholesterol (16.27%). Multiple 164 
imputation was used to replace missing values by applying a chained equation based on outcome 165 
and all potential predictors. 16 imputed datasets were generated for variables with missing 166 
values and were then combined over all imputed datasets by Rubin’s rule to generate final 167 
prediction model estimations. 168 
 169 
Few information was missing (<1%) in the external validation cohort and the complete dataset 170 
was used in the model validation. Based on 244 cerebrovascular inpatient hospitalisations and 95 171 
cerebrovascular re-hospitalisations and 15 predictors or parameters in the development cohort, 172 
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an effective sample size (statistical power more than 80% [15]) of 16 cerebrovascular and 6 173 
cerebrovascular re-hospitalisations per predictor or parameters was acquired. 174 
 175 
Ethical approval 176 
Ethics approval was granted by the Cambridgeshire REC2 Committee (10/H0308/72), and patients 177 
signed-off consent included their agreement for access to inpatient hospitalisation information.   178 
 179 
Model development and external validation 180 
The incident cerebrovascular hospitalisation after the first ninety days of the incident occurrence 181 
of cerebrovascular re-hospitalisation were treated as binary outcome. For each of the 15 182 
candidate predictors or parameters, the Logistic regression was used to estimate the unadjusted 183 
odds ratios. For model development, all candidate predictors were initially included in a 184 
multivariable adjusted Logistic regression model. Fractional polynomials were utilised to model 185 
non-linear relationships between continuous variables and outcomes. 186 
 187 
Lowering lipid treatment was excluded from the multivariable Logistic regression model due to 188 
its statistical insignificance (P>0.1 for log likelihood) through backward elimination. The 189 
eliminated predictor was reinserted into the final prediction models to further examine whether 190 
it changed to be statistically significant. Fractional polynomial parameters were also rechecked 191 
and re-estimated them if necessary. The risk algorithms were then formed for predicting the log 192 
odds of cerebrovascular hospitalisation and cerebrovascular re-hospitalisation by using the 193 
Logistic model regression coefficients multiplied by the parameters included in the models 194 
together with the intercept terms. This process generated equations for the predicted individual 195 
risk=1/(1+e-riskscore), whether the “risk score” is the log odds of cerebrovascular hospitalisation 196 
or cerebrovascular re-hospitalisation from the development models. 197 
 198 
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To facilitate risk score application in primary care, the equations were transferred into risk score 199 
charts. The coefficients from the logistic regression were multiplied by 50 and rounded to the 200 
nearest integer to generate the score per predictor. Multiplication by 50 was used as the majority 201 
of the coefficients was close to an integer, thereby minimizing the rounding effects. The total of 202 
prognostic scores indicates the patient probability of cerebrovascular hospitalisation or 203 
cerebrovascular re-hospitalisation. 204 
 205 
The model performance in terms of the C-statistics and calibration slope (agreement between 206 
observed and predicted risks, where 1.00 as ideal) was assessed. The C-statistics indicates the 207 
possibility that for any randomly sampled pair of diabetic patients with and without outcomes, 208 
the patient with outcomes should have a higher predicted risk [16]. 0.50 of C-statistics indicates 209 
no discrimination and 1.00 of calibration slope means perfect discrimination. Optimism (over-210 
fitting) in model performance was corrected through internal validation by bootstrapping 100 211 
samples of the development data. The model development process was then repeated in every 212 
bootstrap data to generate a model, applied the model coefficient to the same bootstrap data to 213 
quantify apparent performance, and applied the model to the development dataset to examine 214 
model performance (C-statistics and calibration slope) and optimism (difference between the 215 
apparent and test performance). The overall optimism over all models was then estimated.   216 
 217 
Our risk prediction models were applied to individual diabetic patient in the external validation 218 
cohort dataset on the basis of the presence of one or more predictors. The final model 219 
performance in external validation dataset in terms of discrimination by estimating the C-220 
statistics. We also evaluated model calibration by plotting agreement between observed and 221 
predicted probability by decile of the predicted probability.  222 
 223 
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Stata V15.1 was used for all data analyses. We conducted and presented our study in line with the 224 
Transparent Reporting of a multivariate prediction model for Individual Prognosis or Diagnosis 225 
(TRIPOD) guidelines [17]. 226 
 227 
RESULTS 228 
Characteristics of study participants 229 
In the derivation dataset, information of 4,704 type 2 diabetes patients with 244 cerebrovascular 230 
hospitalisations within two years and 95 re-hospitalisations within ninety days of a prior 231 
cerebrovascular hospitalisation were analysed. The validation dataset incorporated information 232 
of 1,121 diabetic patients with 56 cerebrovascular hospitalisations and 21 re-hospitalisations. The 233 
baseline characteristics and candidate predictors of the cohorts are presented in Table-1. Patients 234 
in both cohorts had similar distribution of gender, age, blood pressure and total cholesterol. 235 
Patients in the development cohort dataset had a higher level of HbA1c, low-density lipoprotein 236 
cholesterol, and high-density lipoprotein cholesterol. Compared with the development cohort 237 
dataset, patients in the validation cohort dataset were more likely to take lowering-lipid medicine 238 
and had more cerebrovascular hospitalisation and re-hospitalisation.  239 
 240 
Model development, performance, and validation 241 
In the development dataset, the absolute risks of cerebrovascular hospitalisation within two 242 
years and re-hospitalisation within 90 days post cerebrovascular hospitalisation were 3.76% and 243 
1.46%, respectively. Associations between cerebrovascular hospitalisation and cerebrovascular re-244 
hospitalisation from univariable Logistic regression model are presented in Supplementary Table-245 
1.  246 
 247 
Among the 10 potential predictors (15 parameters), 9 predictors (12 parameters) were 248 
significantly associated with cerebrovascular hospitalisation and re-hospitalisation in our final risk 249 
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prediction model (Table-2). Table-3 presents apparent and internal validation model performance 250 
measurements of the risk prediction model. After the adjustment of optimism, our final risk 251 
prediction model was able to discriminate diabetic patients with and without cerebrovascular 252 
hospitalisation with a C-statistics of 0.7509 (95% confidence interval 0.7436 to 0.7582), and 253 
discriminate diabetic patients with and without cerebrovascular re-hospitalisation with a C-254 
statistics 0.7391 (0.7161 to 0.7451). The agreement between the observed and predicted 255 
probability of outcomes showed good apparent calibrations (Top left of Figure-1 for 256 
cerebrovascular hospitalisation and top right of Figure-1 for cerebrovascular re-hospitalisation). 257 
The calibration slope with optimism adjustment was 0.9961 (0.9928 to 0.9995) and 0.9904 258 
(0.9091 to 1.0525) for cerebrovascular hospitalisation and re-hospitalisation, respectively (Table-259 
3).  260 
 261 
External validation 262 
In our external validation cohort dataset, the incidence of cerebrovascular hospitalisation and re-263 
hospitalisation were 4.99% and 1.87%, respectively. Applying the final models to our independent 264 
external cohort gave a C-statistic of 0.7098 (0.6875 to 0.7321) for cerebrovascular hospitalisation 265 
and 0.7184 (0.7041 to 0.7727) for cerebrovascular re-hospitalisation, and good calibration 266 
(bottom left of Figure-1 for cerebrovascular hospitalisation and bottom right of Figure-1 for 267 
cerebrovascular re-hospitalisation), with the calibration slope 0.9853 (0.9756 to 0.9966) and 268 
0.9846 (0.8894 to 1.0796) for cerebrovascular hospitalisation and re-hospitalisation, respectively. 269 
 270 
Clinical examples 271 
Supplementary Chart-1 presents a real clinical example of the application of risk prediction model 272 
with graphical illustrations (risk score chart) for cerebrovascular hospitalisation and re-273 
hospitalisation risk prediction scores to predict individual two-year risk of cerebrovascular 274 
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hospitalisation and individual risk of re-hospitalisation within ninety days of a previous 275 
cerebrovascular hospitalisation.   276 
 277 
DISCUSSION 278 
Two new risk scores to quantify the individual absolute risk of cerebrovascular hospitalisation 279 
within two years and cerebrovascular re-hospitalisation after ninety days of prior cerebrovascular 280 
hospitalisation in a prospective cohort of type 2 diabetes patients in English primary care settings 281 
have been developed in this study. The two prediction models were validated externally in 282 
another independent prospectively English cohort. The two risk prediction scores revealed useful 283 
discrimination and excellent calibration, with C-statistics of bigger than 0.70 both in our 284 
derivation and external validation cohorts. The two risk prediction scores were derived from 285 
routine clinical measurements recorded and accessible in primary care settings, indicating that 286 
those can be applied in routine primary care (e.g. by embedding in practice software). 287 
 288 
Kothari et al derived a prediction score to predict incident stroke within 10 years among 5,103 289 
newly diagnosed type 2 diabetes patients in the UK Prospective Diabetes Study (UKPDS) [18]. 290 
Age, gender, atrial fibrillation, smoking, systolic blood pressure and lipid ratio were applied in the 291 
final model as predictors. However, the model performance (either discrimination or calibration) 292 
was not evaluated in the study. As the predictors like atrial fibrillation, duration of diabetes in the 293 
UKPDS algorithm were not available in our cohorts, we could not validate the UKPDS in our 294 
cohorts. 295 
Yang et al derived a prediction model to predict incident stroke within 5 years among a Chinese 296 
diabetes population [19]. The splitting sample method was applied to the total sample (7920 type 297 
2 diabetes patients) to generate a derivation sample (3,652 patients) and a validation sample 298 
(3,559 patients). The age, HbA1c, urinary albumin to creatinine ratio and history of coronary heart 299 
disease were included in the final model as predicators. The apparent C-statistics in the derivation 300 
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sample was 0.78. And internal validated calibration suggested good. However, the splitting 301 
method was not suggested in the derivation of prediction models and the external validation was 302 
not implemented in this study. The source population in Yang’s score was a Chinese population, 303 
which is different from our population (Caucasian population). The data from Yang’s score were 304 
derived from a Diabetes registry (Hong Kong Diabetes Registry), which is different from our data 305 
source (primary care data). And the predictor “history of CHD” was not available in our cohorts. 306 
Therefore Yang’s score could not be validated in our cohorts 307 
  308 
Previous risk prediction models have not addressed cerebrovascular disease as a group as a 309 
major reason and health cost for inpatient hospitalisation in type 2 diabetes patients. Being 310 
aware of the individual absolute risk of cerebrovascular hospitalisation in the following year, and 311 
the risk of a new episode (within ninety days) of a recurrent cerebrovascular event (re-312 
hospitalisation) could help clinicians to process more intensive care to patients with a high risk 313 
profile and to decrease inpatient cost.   Implementation approaches could be tested using a 314 
randomized controlled trial format including embedding alerts into practice software and 315 
increasing patient awareness of their risk. 316 
 317 
There are several advantages in our two prediction models over those applied elsewhere. The 318 
two risk algorithms are on the basis of absolute risk derivation and validation in two prospective 319 
cohorts. Routine clinical measurements recorded in primary care settings were used to derive the 320 
two prediction models, which indicates that these measurements can be used straightforwardly 321 
in primary care and are modifiable for external validations in those developed countries that have 322 
primary care electronic health recorded dataset accessible for such objectives. The two scores 323 
can be readily imbedded into online tools for their application in primary care settings. 324 
 325 
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The approaches applied to develop and validate models are close to those models developed 326 
from the CPRD and QResearch studies [20, 21]. The predictors/parameters in the final scores are 327 
accurate and reliable clinical variables routinely recorded in general practices and routinely 328 
updated and reviewed for patients with type 2 diabetes, and are less varied than in other primary 329 
care electronic health record datasets. Moreover, the volume of missing values was relatively 330 
low, which would be less likely to lead to variation in potential external applications, although 331 
multiple imputation was applied.  332 
 333 
We acknowledge that anti-diabetes treatments, diabetes duration, previous history of 334 
cerebrovascular diseases, other type 2 diabetes complications (e.g. renal failure), anti-335 
hypertensive treatments, lifestyle relevant predictors (like smoking), and comorbidities were not 336 
taken into account due to limitations in our original data, but some prognostic factors were very 337 
common in people with diabetes (like antihypertensive treatments which is 81.2% in patients with 338 
type 2 diabetes in the United Kingdom[22]) which would be less discriminated in the model and 339 
we believe that the clinical measurements incorporated in the two prediction models could be 340 
proxies for inaccessible predictors.  Data access limitations also barricaded extending the risk 341 
prediction model to all diabetes complications rather than those relevant to cerebrovascular 342 
hospitalisation.  Due to the similarity between the development and validation cohort datasets, 343 
further more independent external validation (e.g. external data from more developed 344 
countries) are warranted. 345 
 346 
To our knowledge, this is the 1st research to derive risk scores to quantify the two-year risk of 347 
cerebrovascular hospitalisation and re-hospitalisation within ninety days of a prior 348 
hospitalisation. For primary care practice these new two algorithms have two useful implications. 349 
First, these models can be use as screening tools to identify patients with high probability of 350 
cerebrovascular hospitalisation and re-hospitalisation. The two models are based on routine 351 
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accessible clinical information recorded in primary care settings and evaluated by diabetes care 352 
teams.  They can be imbedded into general practice computer systems or integrated into a 353 
mobile application for a handheld mobile device for ease of utilisation. Secondly, the risk scores 354 
could be applied to establish new thresholds of treatment in primary care practice through 355 
consensus development of guidance. 356 
 357 
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FIGURE LEGENDS 447 
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Figure-1. Assessing calibration in the derivation cohort (left) and the validation cohort (right) for 448 
cerebrovascular hospitalisation (above panel) and cerebrovascular re-hospitalisation (below 449 
panel) 450 
 451 
TABLES 452 
Table-1. Characteristics of study participants in development cohort and external validation 453 
cohort. 454 
  Development cohort Validation cohort 
Number of participants 4,704 1,121 
Cerebrovascular hospitalisation, n (%) 244 (3.76) 56 (4.99) 
Cerebrovascular rehospitalisation, n (%) 95 (1.46) 21 (1.87) 
Age a baseline, years 65.0±16.3 65.5±11.4 
Female gender, n (%) 1,919 (40.8) 444 (39.6) 
Systolic blood pressure, mmHg 134.5±16.0 139.7±20.2 
Diastolic blood pressure, mmHg 76.3±10.0 75.5±11.5 
Total cholesterol, mmol/L 4.3±1.2 4.2±1.7 
High density lipoprotein cholesterol, mmol/L 1.3±0.6 1.1±1.2 
Low density lipoprotein cholesterol, mmol/L 2.5±1.4 1.4±3.0 
Body mass index, kg/m2 30.8±6.9 32.2±6.0 
Glycated haemoglobin (HbA1c), mmol/mol / % 61.5±17.2 / 7.8±3.7 56.2±15.1 / 7.3±3.5 
Taking lipid Lowering treatment, n (%) 3,342 (71.4) 731 (65.2) 
 455 
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 Table-2. Multivariable model estimation for cerebrovascular hospitalisation and re-hospitalisation 456 
risk among type 2 diabetes patients in development cohort 457 
Predictors/Parameters Coefficient 95% Confidence Interval 
Cerebrovascular Hospitalisation 
Male gender 0.3313 (0.2909 to 0.3716) 
Glycated haemoglobin (HbA1c) ≥ 57 mmol/mol (7.4%) -0.1259 (-0.1638 to -0.0879) 
(Body mass index/10)^3 0.0624 (0.0520 to 0.0728) 
((Body mass index/10)^3)*ln(Body mass index/10) -0.0371 (-0.0435 to -0.0307) 
Systolic blood pressure/100 1.6098 (0.4821 to 2.7375) 
(Systolic blood pressure/100)^2 -0.2216 (-0.6220 to 0.1788) 
(Diastolic blood pressure/100)^-2 -0.0239 (-0.0483 to 0.0005) 
Diastolic blood pressure/100 -2.1136 (-2.3820 to -1.8452) 
(Total cholesterol/10)^-2 -0.0056 (-0.0079 to -0.0033) 
(Total cholesterol/10)^2 0.8866 (0.6862 to 1.0870) 
(High density lipoprotein cholesterol)^3 0.0851 (0.0563 to 0.1139) 
((High density lipoprotein cholesterol)^3)*ln(High 
density lipoprotein cholesterol) -0.0892 (-0.1192 to -0.0593) 
Low density lipoprotein cholesterol/10 -0.6356 (-0.9387 to -0.3325) 
(Low density lipoprotein cholesterol/10)^3 0.5521 (-0.2076 to 1.3117) 
Baseline age>=70 years 1.0647 (1.0213 to 1.1080) 
Constant -4.7571 (-5.5717 to -3.9426) 
Cerebrovascular Re-hospitalisation 
Male gender 0.1359 (0.0741 to 0.1978) 
Glycated haemoglobin (HbA1c)  ≥ 57 mmol/mol (7.4%) -0.2318 (-0.2914 to -0.1722) 
(Body mass index/10)^3 0.0618 (0.0445 to 0.0792) 
((Body mass index/10)^3)*ln(Body mass index/10) -0.0383 (-0.0491 to -0.0274) 
Systolic blood pressure/100 -2.4341 (-3.7885 to -1.0798) 
(Systolic blood pressure/100)^2 1.2371 (0.7573 to 1.7169) 
(Diastolic blood pressure/100)^-2 0.6846 (0.4897 to 0.8794) 
 19 
 
((Diastolic blood pressure/100)^-2)*ln(Diastolic blood 
pressure/100) 0.3780 (0.2058 to 0.5501) 
(Total cholesterol/10)^3 -1.4790 (-2.3056 to -0.6524) 
((Total cholesterol/10)^3)*ln(Total cholesterol/10) -11.2187 (-13.7345 to -8.7029) 
(High density lipoprotein cholesterol)^3 0.1949 (0.1535 to 0.2362) 
((High density lipoprotein cholesterol)^3)*ln(High 
density lipoprotein cholesterol) -0.1992 (-0.2412 to -0.1572) 
Low density lipoprotein cholesterol/10 0.0291 (-0.4999 to 0.5582) 
(Low density lipoprotein cholesterol/10)^3 -1.6879 (-3.0975 to -0.2784) 
Baseline age>=70 years 1.1117 (1.0424 to 1.1811) 
Constant -6.2027 (-7.2062 to -5.1991) 
 458 
 459 
 460 
  20 
Table-3. Model performance statistics (with 95% confidence interval) 
 
Derivation 
External validation Measure  Apparent performance Test performance 
Average 
optimism 
Optimism corrected 
performance 
 Cerebrovascular Hospitalisation 
C-statistic 1.0000 (0.9967 to 1.0034) 0.9961 (0.9884 to 1.0038) 0.0039 0.9961 (0.9928 to 0.9995) 0.9853 (0.9756 to 0.9966) 
Calibration slope 0.7546 (0.7473 to 0.7619) 0.7509 (0.7454 to 0.7564) 0.0037 0.7509 (0.7436 to 0.7582) 0.7098 (0.6875 to 0.7321) 
 Cerebrovascular Re-hospitalisation 
C-statistic 1.0000 (0.9557 to 1.0443) 0.9904 (0.9187 to 1.0621) 0.0096 0.9904 (0.9091 to 1.0525) 0.9846 (0.8894 to 1.0796) 
Calibration slope 0.7476 (0.7403 to 0.7549) 0.7391 (0.7246 to 0.7536) 0.0085 0.7391 (0.7161 to 0.7451) 0.7184 (0.7041 to 0.7327) 
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